Citius Oncology reports positive topline results from Phase 1 clinical trial of LYMPHIR combination
CMIC agrees agentic AI partnership with Bluenote
GenomOncology partners with WeTrials to support CNS cancer clinical trials
Target ALS awards two-year research grant to AcuraStem for advancing therapeutics targeting SYF2
Ascletis reports Phase II weight‑loss results for ASC30 depot formulation
NS Pharma and NCNP report 4.5-year brogidirsen data for DMD treatment
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Koselugo approved in Canada for adults with NF1 and inoperable plexiform neurofibromas
Bristol Myers Squibb reports positive Phase 3 results for oral mezigdomide in multiple myeloma
Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis
Agilent to acquire Biocare Medical for USD950m to expand pathology portfolio
Ipsen withdraws tazverik across all markets following safety concerns in lymphoma trial
GSK licences global rights to linerixibat to Alfasigma in USD300m deal
IDEAYA Biosciences enrols first patient in Phase 1 trial of PRMT5 inhibitor IDE892